source
- Scancell to list on Nasdaq after reverse merger with Neuphoria, funds $89M for melanoma immunotherapy trialScancell announced that it will become a publicly traded company on Nasdaq after completing an all‑stock reverse merger with Neophobia Therapeutics. The transaction gives Scancell a new ticker, SCL…
- Merck CEO warns Congress that restricting US-China biotech deals could cost America its biotech leadershipMerck CEO Rob Davis told Congress and the Trump administration that limiting or cutting off US-China dealmaking would jeopardize US biotech leadership. He emphasized that collaboration with Chines…